Business Wire

CA-ARMIS

22.1.2024 14:01:31 CET | Business Wire | Press release

Share
Cybersecurity Attack Attempts More Than Doubled, Increasing 104% in 2023

Armis, the asset intelligence cybersecurity company, today announced The Anatomy of Cybersecurity: A Dissection of 2023's Attack Landscape. The 2023 analysis of Armis’ proprietary data offers critical insight into the multifaceted challenges global organizations face when it comes to protecting the entire attack surface. Report findings serve as a blueprint to help security teams worldwide prioritize efforts to reduce cyber risk exposure in 2024.

The report found that global attack attempts more than doubled in 2023, increasing 104%. Utilities (over 200% increase) and Manufacturing (165% increase) were the most at risk industries. Attack attempts peaked in July, with communications devices, imaging devices and manufacturing devices experiencing intensified targeting during this period.

“Armis found that not only are attack attempts increasing, but cybersecurity blind spots and critical vulnerabilities are worsening, painting prime targets for malicious actors,” said Nadir Izrael, CTO and Co-Founder, Armis. “It’s critical that security teams leverage similar intelligence defensively so that they know where to prioritize efforts and fill these gaps to mitigate risk. We hope that by sharing these insights, global businesses and governments will leverage them to immediately pinpoint what they should be focusing on to improve their cybersecurity posture this year to keep critical infrastructure, economies and society safe and secure.”

Key findings of The Anatomy of Cybersecurity: A Dissection of 2023's Attack Landscape include:

Geopolitical tensions exacerbate the cybersecurity landscape

  • Cyberwarfare grew more widespread in 2023. Top industries exposed to attack from Chinese and Russian actors were those within Manufacturing, Educational Services and Public Administration.
    • In manufacturing, .cn and .ru domains contributed to an average of 30% of monthly attack attempts, while attacks from these domains on Educational Services have risen to about 10% of total attacks.

Legacy technology steepens incline of cybersecurity pros’ existing up-hill battle

  • Older Windows server OS versions (2012 and earlier) are 77% more likely to experience attack attempts compared to newer Windows Server versions.
    • This vulnerability is particularly evident in the server environment, with nearly a quarter of server versions facing end-of-support (EoS) scenarios. The Educational Services industry has a significantly higher percentage of servers (41%) with unpatched weaponized Common Vulnerabilities and Exposures (CVEs), compared to the general average of 10%.
  • Industries still using end-of-life (EoL) or EoS OSs that are no longer actively supported or patched for vulnerabilities and security issues by the manufacturer: Educational Services (18%), Retail (14%), Healthcare (12%), Manufacturing (11%) and Public Administration (10%).

Businesses struggle with effective vulnerability prioritization and remediation

  • There were over 65,000 unique CVEs discovered in 2023.
  • Wearable devices have the highest percentage (93%) of unpatched CVEs.
  • A third of all devices are still not patched for Log4Shell.
  • Patch rates for critical CVEs are not prioritized:
    • Low CVEs: 11% patch rate
    • Medium CVEs: 58% patch rate
    • High CVEs: 64% patch rate
    • Critical CVEs: 55% patch rate
  • Irrespective of the weaponization status of a CVE, organizations consistently grapple with patch rates at 62% for non-weaponized and 61% for weaponized vulnerabilities.

“Blueprints like this report are invaluable as they help teams focus limited resources on efforts with the greatest impact and with the insights to tell data-driven stories in justification of cross-team priorities,” said Curtis Simpson, CISO, Armis. “Using hindsight and analyzed data could allow CISOs to focus 2024 efforts on segmenting legacy technology, prioritizing exposures of greatest significance, and utilizing AI-driven technologies that can assist security teams with defending and managing the attack surface in real-time.”

Proprietary data leveraged for this report was mined from Armis’ Asset Intelligence Engine. The Armis Asset Intelligence Engine is a collective AI-powered knowledge base, monitoring billions of assets worldwide, in order to identify cyber risk patterns and behaviors. It feeds the Armis Centrix™ platform with unique, actionable cyber intelligence to detect and address real-time threats across the entire attack surface.

To read the full report, The Anatomy of Cybersecurity: A Dissection of 2023's Attack Landscape, please visit: https://www.armis.com/anatomy-of-cybersecurity

Learn more about The Armis Asset Intelligence Engine here: https://www.armis.com/platform/armis-asset-intelligence-engine/

About Armis

Armis, the asset intelligence cybersecurity company, protects the entire attack surface and manages the organization's cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240122998889/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye